In vivo, observed changes in efficacy of an immunotherapy administered at different days following subcutaneous tumor challenge was consistent with a progressive loss in time of MHC class I antigen presentation, which was largely independent of changes in IFNG within the tumor microenvironment and the number of TILs. This evidence concerns the gene IFNG and neoplasm.